Bavarian Nordic's vaccine acquisition expecting to close within three months
The deal with Emergent Biosolutions was signed some weeks ago, and final approvals are falling into place, says Bavarian Nordic CFO Henrik Juuel.
by marketwire, translated by daniel pedersen
In less than three months, Bavarian Nordic expects to complete the transaction of a newly acquired vaccine portfolio from Emergent Biosolutions. The deal was signed around two weeks ago, and the company is in the midst of securing the final approvals.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
Bavarian Nordic completes discounted directed issue
For subscribers
